Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy

Details Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy

2011-03-08

2011-03-08

Balasubramanian, Venkataraman (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

C514S275000, C514S235800, C514S252140, C544S295000, C544S122000

Reexamination Certificate

active

07902361

ABSTRACT:
The present invention relates to compounds of formula I, or pharmaceutically acceptable salts thereof,wherein R1and R5are each independently H, C(ORj′) or a hydrocarbyl group optionally substituted by one or more R6groups;R2, R3, and R4are each independently H, alkyl or alkenyl, each of which may be optionally substituted with one or more R7groups;R6and R7are each independently halogen, NO2, CN, (CH2)mORa, O(CH2)nORb, (CH2)pNRcRd, CF3, COORe, CONRfRg, CORh, SO3H, SO2Ri, SO2NRjRk, (CH2)qNRa′CORg′, Rf′, (CH2)rNRb′SO2Rh′, SO2NRd′Ri′, SO2NRe′(CH2)sORc′, heterocycloalkyl or heteroaryl, wherein said heterocycloalkyl and heteroaryl may be optionally substituted by one or more substituents selected from aralkyl, sulfonyl, Rmand CORn;Rg′, Rh′, Ri′and Rj′are each independently selected from alkyl, aryl, aralkyl and heteroaryl, each of which may be optionally substituted with one or more substituents selected from halogen, OH, NO2, NH2CF3and COOH;m, p, q and r are each independently 0, 1, 2 or 3;n and s are each independently 1, 2, or 3; andRa-nand Ra′-f′are each independently H or alkyl.Further aspects of the invention relate to pharmaceutical compositions comprising such compounds, and their use in the preparation of a medicament for treating one or more of the following: a proliferative disorder, a viral disorder, a CNS disorder, a stroke, alopecia and diabetes.

REFERENCES:
patent: 6221873 (2001-04-01), Havlicek et al.
patent: 6531479 (2003-03-01), Wang
patent: 6569833 (2003-05-01), Fahraeus
patent: 6699854 (2004-03-01), Wang
patent: 6703395 (2004-03-01), Havlicek
patent: 6962792 (2005-11-01), Ball
patent: 7045519 (2006-05-01), Nuss et al.
patent: 7427627 (2008-09-01), Wang et al.
patent: 7432260 (2008-10-01), Wang et al.
patent: WO-97/19065 (1997-05-01), None
patent: WO-03/029248 (2003-04-01), None
patent: WO-2004/043467 (2004-05-01), None
patent: WO-2004/043953 (2004-05-01), None
patent: WO-2004/056368 (2004-07-01), None
Cecil Textbook of Medicine, edited by Bennet, J.C., and Plum F., 20th edition,vol. 1, 1004-1010, 1996.
Malumbres et al., Trends in Biochemical Sciences, 30(11), 630-641, 2005.
Lolli et al., Cell Cycle 4:4,572-577, 2005.
Sherr et al., Genes & Development 18, 2699-2711,2004.
Fischer Cell Cycle 3:6, 742-746, 2004.
Blain et al., The Journal of Biological Chemistry, 272(41), 25863-25872, 1997.
LuValle et al., Frontiers in Bioscience, 5, d493-503,2000.
Patel et al. Biochem. Soc. Trans. 32(5), 803-808,2004.
Jope et al., Trends in Biochemical Sciences 29(2), 95-102, 2004.
Mass, R. D., Int. J. Radiation Oncology Bio. Phys.vol. 58(3): 932-940, 2004.
Fabbro et al. Pharmacology & therapeutics 93, 79-98, 2002.
U.S. Appl. No. 10/646,267, filed Aug. 22, 2003.
U.S. Appl. No. 10/153,441, filed May 21, 2002.
U.S. Appl. No. 10/671,747, filed Sep. 26, 2003.
U.S. Appl. No. 11/507,929, filed Aug. 21, 2006.
U.S. Appl. No. 10/671,747, filed Sep. 24, 2003.
U.S. Appl. No. 10/742,237, filed Dec. 18, 2003.
U.S. Appl. No. 10/810,767, filed Mar. 26, 2004.
U.S. Appl. No. 11/433,312, filed May 11, 2006.
U.S. Appl. No. 10/846,217, filed May 14, 2004.
U.S. Appl. No. 10/914,842, filed Aug. 10, 2004.
U.S. Appl. No. 10/991,942, filed Nov. 17, 2004.
U.S. Appl. No. 10/507,883, filed Sep. 15, 2004.
U.S. Appl. No. 10/952,575, filed Sep. 27, 2004.
U.S. Appl. No. 11/033,692, filed Jan. 11, 2005.
U.S. Appl. No. 11/238,533, filed Sep. 28, 2005.
U.S. Appl. No. 11/051,059, filed Feb. 4, 2005.
U.S. Appl. No. 11/124,636, filed May 5, 2005.
U.S. Appl. No. 11/122,331, filed May 3, 2005.
U.S. Appl. No. 11/121,753, filed May 3, 2005.
U.S. Appl. No. 11/124,622, filed May 5, 2005.
U.S. Appl. No. 11/140,136, filed May 26, 2005.
U.S. Appl. No. 11/129,198, filed May 13, 2005.
U.S. Appl. No. 11/192,893, filed Jul. 28, 2005.
U.S. Appl. No. 11/301,070, filed Dec. 9, 2005.
U.S. Appl. No. 11/326,805, filed Jan. 6, 2006.
U.S. Appl. No. 11/339,058, filed Jan. 25, 2006.
U.S. Appl. No. 11/339,059, filed Jan. 25, 2006.
U.S. Appl. No. 10/588,372, filed Aug. 3, 2006.
International Search Report for PCT/GB2004/004465, dated Apr. 24, 2006.

Affiliated with

Also associated with

Rating

Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrimidin-4-yl-3, 4-thione compounds and their use in therapy will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2737338